+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ventilator Associated Pneumonia (VAP) Drug Pipeline Report 2020 - Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

  • ID: 4849267
  • Drug Pipelines
  • October 2019
  • Region: Global
  • 80 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Destiny Pharma Ltd
  • Fedora Pharmaceuticals
  • Meiji Seika Pharma Co Ltd
  • Motif Bio Plc
  • Polyphor AG
  • MORE
Ventilator Associated Pneumonia (VAP) Drug pipeline report- 2020 is an annual R&D review of Ventilator Associated Pneumonia (VAP) pipeline candidates. The report presents the current status of all major Ventilator Associated Pneumonia (VAP) therapeutic compounds. Detailed insights into Ventilator Associated Pneumonia (VAP) pipeline development, current status, companies, drug profiles and Ventilator Associated Pneumonia (VAP) preclinical and clinical trials are included.

2020 Ventilator Associated Pneumonia (VAP) Pipeline Market Insights
Ventilator Associated Pneumonia (VAP) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Ventilator Associated Pneumonia (VAP) therapies, pipeline by phase and others are included.

Ventilator Associated Pneumonia (VAP) Pipeline Drug Profiles
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Ventilator Associated Pneumonia (VAP) Therapeutic Drug Candidates
Both active and inactive Ventilator Associated Pneumonia (VAP) pipeline drug candidates are included in the report

Ventilator Associated Pneumonia (VAP) Clinical Trials and Preclinical Studies
Ventilator Associated Pneumonia (VAP) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Ventilator Associated Pneumonia (VAP) Pipeline Market Developments
Ventilator Associated Pneumonia (VAP) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Ventilator Associated Pneumonia (VAP) Pipeline Companies in Active Development
The report analyzes Ventilator Associated Pneumonia (VAP) pipeline of the below companies-
Aridis Pharmaceuticals Inc, AstraZeneca Plc, Cumberland Pharmaceuticals Inc, CytaCoat AB, Destiny Pharma Ltd, Dong-A Socio Holdings Co Ltd, Evaxion Biotech ApS, Fedora Pharmaceuticals, MedImmune LLC, Meiji Seika Pharma Co Ltd, Merck & Co Inc, Motif Bio Plc, Nabriva Therapeutics plc, Polyphor AG, Shionogi & Co Ltd, Spero Therapeutics Inc, Tetraphase Pharmaceuticals Inc, TGV Laboratories Inc, Wockhardt Ltd

Report Coverage
- What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included
- Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others
- Companies
19 Companies investing in Ventilator Associated Pneumonia (VAP) pipeline from discovery stage to pre-registration phase are included
- Drug profiles
Over 10 details of each Ventilator Associated Pneumonia (VAP) pipeline candidate are included
- Company Profiles
Business overview and contact details of all companies operating in the industry are provided
- Market Developments
News, Developments and other recent industry developments are included
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Destiny Pharma Ltd
  • Fedora Pharmaceuticals
  • Meiji Seika Pharma Co Ltd
  • Motif Bio Plc
  • Polyphor AG
  • MORE
1. Ventilator Associated Pneumonia (VAP) Pipeline Market Insights, 2020
1.1 Ventilator Associated Pneumonia (VAP) Disease Overview
1.2 Ventilator Associated Pneumonia (VAP) Drug Pipeline Snapshot, 2020
1.2.1 Ventilator Associated Pneumonia (VAP) Pipeline Drugs by Phase
1.2.2 Ventilator Associated Pneumonia (VAP) Pipeline Drugs by Company
1.2.3 Ventilator Associated Pneumonia (VAP) Pipeline Drugs by Mechanism of Action
1.2.4 Ventilator Associated Pneumonia (VAP) Pipeline Drugs by Route of Administration

2. Ventilator Associated Pneumonia (VAP) Company wise Pipeline Details
Aridis Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
AstraZeneca Plc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Cumberland Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
CytaCoat AB Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Destiny Pharma Ltd Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Dong-A Socio Holdings Co Ltd Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Evaxion Biotech ApS Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Fedora Pharmaceuticals Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
MedImmune LLC Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Meiji Seika Pharma Co Ltd Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Merck & Co Inc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Motif Bio Plc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Nabriva Therapeutics plc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Polyphor AG Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Shionogi & Co Ltd Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Spero Therapeutics Inc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Tetraphase Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
TGV Laboratories Inc Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Wockhardt Ltd Ventilator Associated Pneumonia (VAP) Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
3. Ventilator Associated Pneumonia (VAP) Drug Pipeline Profiles
3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. Ventilator Associated Pneumonia (VAP) Pipeline News and Developments

5. Appendix
5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aridis Pharmaceuticals Inc
  • AstraZeneca Plc
  • Cumberland Pharmaceuticals Inc
  • CytaCoat AB
  • Destiny Pharma Ltd
  • Dong-A Socio Holdings Co Ltd
  • Evaxion Biotech ApS
  • Fedora Pharmaceuticals
  • MedImmune LLC
  • Meiji Seika Pharma Co Ltd
  • Merck & Co Inc
  • Motif Bio Plc
  • Nabriva Therapeutics plc
  • Polyphor AG
  • Shionogi & Co Ltd
  • Spero Therapeutics Inc
  • Tetraphase Pharmaceuticals Inc
  • TGV Laboratories Inc
  • Wockhardt Ltd
Note: Product cover images may vary from those shown
Adroll
adroll